Tamara Isakova1, Timothy E Craven2, Jungwha Lee3, Julia J Scialla4, Huiliang Xie4, Patricia Wahl4, Santica M Marcovina5, Robert P Byington6, Myles Wolf7. 1. Department of Medicine, Institute of Public Health and Medicine and tamara.isakova@northwestern.edu. 2. Departments of Biostatistical Sciences and. 3. Department of Preventative Medicine, Division of Biostatistics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; 4. Division of Nephrology and Hypertension, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida; and. 5. Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington School of Medicine, Seattle, Washington. 6. Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University Health Sciences, Winston-Salem, North Carolina; 7. Department of Medicine, Institute of Public Health and Medicine and.
Abstract
BACKGROUND AND OBJECTIVES: High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consisted of a random subcohort of 590 patients with type 2 diabetes without prevalent CKD at baseline, 124 of whom developed incident CKD during follow-up, and 520 additional patients with incident CKD outside the random subcohort. The association between serum intact fibroblast growth factor 23 and incident CKD, defined as the new onset of eGFR<60 ml/min per 1.73 m(2) that represented a ≥25% decrease from baseline in an individual with eGFR≥60 ml/min per 1.73 m(2) and no microalbuminuria (<30 mg/g creatinine) at baseline, was tested. RESULTS: The mean baseline eGFR in the random subcohort was 90.9±22.7 ml/min per 1.73 m(2). During a median follow-up of 4.7 years, there was a total of 644 patients with incident CKD. The median baseline fibroblast growth factor 23 level was modestly higher among patients with incident CKD versus controls (43.5, interquartile range=34.7-55.1 versus 39.8, interquartile range=31.9-49.5 pg/ml; P<0.001). Higher baseline fibroblast growth factor 23 levels were associated with higher risk of incident CKD in unadjusted and demographics-adjusted models, but the effect was attenuated after additional adjustment for clinical risk factors and baseline eGFR (hazard ratio per SD of natural log fibroblast growth factor 23, 1.09; 95% confidence interval, 0.94 to 1.27), which was the strongest predictor of incident CKD. Consistent with the results of primary analyses, baseline fibroblast growth factor 23 was not associated with eGFR slope. CONCLUSIONS: Higher fibroblast growth factor 23 levels are not independently associated with higher risk of incident CKD in patients with type 2 diabetes.
RCT Entities:
BACKGROUND AND OBJECTIVES: High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consisted of a random subcohort of 590 patients with type 2 diabetes without prevalent CKD at baseline, 124 of whom developed incident CKD during follow-up, and 520 additional patients with incident CKD outside the random subcohort. The association between serum intact fibroblast growth factor 23 and incident CKD, defined as the new onset of eGFR<60 ml/min per 1.73 m(2) that represented a ≥25% decrease from baseline in an individual with eGFR≥60 ml/min per 1.73 m(2) and no microalbuminuria (<30 mg/g creatinine) at baseline, was tested. RESULTS: The mean baseline eGFR in the random subcohort was 90.9±22.7 ml/min per 1.73 m(2). During a median follow-up of 4.7 years, there was a total of 644 patients with incident CKD. The median baseline fibroblast growth factor 23 level was modestly higher among patients with incident CKD versus controls (43.5, interquartile range=34.7-55.1 versus 39.8, interquartile range=31.9-49.5 pg/ml; P<0.001). Higher baseline fibroblast growth factor 23 levels were associated with higher risk of incident CKD in unadjusted and demographics-adjusted models, but the effect was attenuated after additional adjustment for clinical risk factors and baseline eGFR (hazard ratio per SD of natural log fibroblast growth factor 23, 1.09; 95% confidence interval, 0.94 to 1.27), which was the strongest predictor of incident CKD. Consistent with the results of primary analyses, baseline fibroblast growth factor 23 was not associated with eGFR slope. CONCLUSIONS: Higher fibroblast growth factor 23 levels are not independently associated with higher risk of incident CKD in patients with type 2 diabetes.
Authors: Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix Journal: Ann Intern Med Date: 2010-05-18 Impact factor: 25.391
Authors: Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf Journal: JAMA Date: 2011-06-15 Impact factor: 56.272
Authors: T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech Journal: Diabetologia Date: 2010-11-04 Impact factor: 10.122
Authors: Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf Journal: Kidney Int Date: 2011-03-09 Impact factor: 10.612
Authors: Myles Wolf; Miklos Z Molnar; Ansel P Amaral; Maria E Czira; Anna Rudas; Akos Ujszaszi; Istvan Kiss; Laszlo Rosivall; Janos Kosa; Peter Lakatos; Csaba P Kovesdy; Istvan Mucsi Journal: J Am Soc Nephrol Date: 2011-03-24 Impact factor: 10.121
Authors: Martin J Landray; Jonathan R Emberson; Lisa Blackwell; Tanaji Dasgupta; Rosita Zakeri; Matthew D Morgan; Charlie J Ferro; Susan Vickery; Puja Ayrton; Devaki Nair; R Neil Dalton; Edmund J Lamb; Colin Baigent; Jonathan N Townend; David C Wheeler Journal: Am J Kidney Dis Date: 2010-10-30 Impact factor: 8.860
Authors: Tamara Isakova; Timothy E Craven; Julia J Scialla; Thomas L Nickolas; Adrian Schnall; Joshua Barzilay; Ann V Schwartz Journal: Bone Date: 2015-04-30 Impact factor: 4.398
Authors: Michel Chonchol; Berenice Gitomer; Tamara Isakova; Xuan Cai; Isidro Salusky; Renata Pereira; Kaleab Abebe; Vicente Torres; Theodor I Steinman; Jared J Grantham; Arlene B Chapman; Robert W Schrier; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2017-07-13 Impact factor: 8.237
Authors: Rupal Mehta; Xuan Cai; Jungwha Lee; Dawei Xie; Xue Wang; Julia Scialla; Amanda H Anderson; Jon Taliercio; Mirela Dobre; Jing Chen; Michael Fischer; Mary Leonard; James Lash; Chi-Yuan Hsu; Ian H de Boer; Harold I Feldman; Myles Wolf; Tamara Isakova Journal: Am J Kidney Dis Date: 2019-12-19 Impact factor: 8.860
Authors: David A Drew; Ronit Katz; Stephen Kritchevsky; Joachim H Ix; Michael G Shlipak; Anne B Newman; Andy Hoofnagle; Linda Fried; Mark J Sarnak; Orlando M Gutierrez Journal: Am J Nephrol Date: 2018-04-05 Impact factor: 3.754
Authors: Laura Grau; Berenice Gitomer; Bryan McNair; Myles Wolf; Peter Harris; Godela Brosnahan; Vicente Torres; Theodore Steinman; Alan Yu; Arlene Chapman; Michel Chonchol; Kristen L Nowak Journal: Kidney360 Date: 2020-07-30